A Phase 1/2 Study of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis.
Abroad (travel likely)RecruitingPHASE1, PHASE2
Conditions
Healthy Volunteers · Systemic Sclerosis (SSc) · Scleroderma, Systemic · Scleroderma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Nucleus Network, Melbourne, Victoria, Australia
Peking University Third Hospital, Beijing, China
Nanjing Drum Tower Hospital, Nanjing, China
Study leads
Salim Mujais
Study Director
Prolium Bioscience, Inc